OptimizeRx Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed April 15, 2024. This annual report compares FY2023 with FY2022, rather than reporting only the fourth quarter.
Business context
OptimizeRx provides digital healthcare marketing and patient-engagement technology connecting life sciences companies with healthcare providers and patients. Its offerings include AI-enabled audience development and activation through DAAP, omnichannel media execution, and financial messaging. The company reported a network reaching more than two million U.S. healthcare providers.
The company acquired Medicx Health, a consumer-focused omnichannel marketing and analytics business, on October 24, 2023. Management’s strategy is to expand existing customer relationships and enterprise engagements, grow DAAP, and pursue operational and product synergies with Medicx.
Financial performance and position
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Revenue | $71.5 million | $62.5 million | Up 15%; 7.3 percentage points of growth came from Medicx, with the remainder attributed to stronger DAAP sales. |
| Gross profit / margin | $42.9 million / 60.0% | $39.0 million / 62.4% | Gross profit increased, but margin declined, primarily due to channel-partner mix. |
| Operating expenses | $69.3 million | $51.3 million | Up about 35%, including impairment, acquisition transaction costs, disposal loss, and higher compensation-related costs. |
| Operating loss | $26.4 million | $12.3 million | Loss widened. |
| Net loss | $17.6 million; $1.03 per diluted share | $11.4 million; $0.64 per diluted share | Loss widened despite higher revenue; includes significant noncash expenses and a $7.6 million income tax benefit in 2023. |
| Cash from operations | Used $7.2 million | Provided $10.7 million | 2023 cash use reflected the net loss and working-capital investment, including higher receivables. |
| Cash and short-term investments | $13.9 million cash; no short-term investments | $18.2 million cash and $55.9 million short-term investments | Investments were liquidated during 2023, in part to fund the acquisition. |
| Working capital / current ratio | $36.4 million / 3.0 | $90.2 million / 11.7 | Liquidity declined, primarily due to the acquisition and share repurchases. |
| Debt | $38.3 million principal outstanding | None | Term loan bears a variable rate; 14.1% at year-end. Effective FY2023 rate, including specified charges, was 19.6%. |
At December 31, 2023, total assets were $183.4 million, total liabilities were $56.8 million, and stockholders’ equity was $126.6 million. Goodwill was $78.4 million and net intangible assets were $49.4 million.
Material changes and unusual items
- Medicx was acquired for approximately $96.0 million of consideration, consisting of $83.9 million net cash transferred and $12.1 million in common stock. Medicx contributed $4.5 million of revenue and $0.3 million of net income from acquisition through year-end. Unaudited pro forma FY2023 revenue and net loss, assuming Medicx had been included for the full year, were $97.1 million and $18.6 million, respectively.
- The company recorded $6.7 million of impairment charges on intangible assets related primarily to non-core products, and a $2.1 million loss on disposal of a business. Goodwill was not impaired.
- Acquisition transaction costs were approximately $4.5 million. Stock-based compensation remained substantial at $13.7 million, though down from $15.7 million in 2022.
- A $7.6 million income tax benefit reflected a partial release of the valuation allowance on deferred tax assets; realization of remaining tax assets depends on future taxable income.
- Operating cash flow moved from positive $10.7 million in 2022 to negative $7.2 million in 2023. Investing cash use was $25.3 million and financing activities provided $28.2 million, including term-loan proceeds and $7.5 million of share repurchases.
- DAAP deals increased to 24 from six in 2022. Net revenue retention rose to 105% from 90%; average revenue per top-20 pharmaceutical manufacturer increased to $2.57 million from $2.14 million.
Outlook, risks, and contingencies
Management stated that operating cash generation and existing cash and cash equivalents should be sufficient for current operations and planned growth over the next 12 months, and that it does not anticipate needing additional cash for operations. Significant cash acquisitions could require additional financing. The filing does not provide numerical revenue, earnings, or margin guidance.
- Debt and liquidity: The term loan is secured by company and subsidiary assets, has a stated year-end rate of 14.1%, and includes leverage and minimum-liquidity covenants. The company reported covenant compliance at year-end. Scheduled principal payments include $2.0 million in each of 2024, 2025, and 2026, with $32.3 million due in 2027. Rising rates could increase debt service costs.
- Customer and partner concentration: The top five customers represented approximately 44% of 2023 revenue; one customer represented 14.4%. The largest EHR/e-prescribing partner generated 36.4% of revenue, up from 31.8% in 2022. Loss or disruption of major relationships could materially affect results.
- Committed partner payments: Minimum payments for media, data, or messaging capabilities totaled approximately $24.7 million through 2028, including $10.6 million in 2024.
- Profitability and execution: The company has a history of losses and warned that profitability depends on revenue growth and expense management. Acquisition integration, growth management, product development, competition, and seasonality could affect results.
- Internal controls: Management identified a material weakness involving controls to ensure third-party service-provider data is complete and accurate. Disclosure controls and internal control over financial reporting were assessed as ineffective at year-end. Remediation plans include obtaining SOC 1 Type 2 reports or performing alternative evaluations and testing.
- Other risks: The filing highlights healthcare privacy and regulatory compliance, cybersecurity and service continuity, inflation and economic uncertainty, international operations, potential goodwill or intangible-asset impairment, and share-price volatility. No material legal proceedings or material cybersecurity incidents were reported. The company said it discontinued PHI processing in late 2023, although certain PHI remained stored for customer access.
The financial statements received an unqualified audit opinion. The auditor identified revenue recognition and the Medicx acquisition’s intangible-asset valuation as critical audit matters; the auditor was not engaged to, and did not, opine on internal-control effectiveness.
Important facts for investors to verify
- Whether DAAP growth, customer retention, and Medicx integration translate into sustained organic growth and improved gross margins.
- Progress remediating the third-party data controls material weakness, and whether subsequent filings report effective controls.
- Cash conversion and receivables collection, given negative 2023 operating cash flow and higher year-end accounts receivable.
- Ability to meet loan covenants and refinance or repay the large 2027 maturity; confirm current interest rate, covenant headroom, and any later amendments.
- Revenue exposure to the largest customers and channel partner, and the economics of the related revenue-share and minimum-payment commitments.
- Key assumptions supporting Medicx purchase accounting, remaining intangible values, and future impairment testing; also verify realization assumptions for deferred tax assets.